Review the material listed in this clinical trial for breast cancer drug: A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer and comment on -The inclusion and exclusion criteria used in recruiting patients for Phase I and II trials. How does this differ from a regular Phase-I trial? Discuss the study results and the outcome of the trial. Provide thoughts on challenges involved in designing a phase-I/II clinical trial for an anti breast cancer drug. Provide thoughts on personalized immunotherapy for cancer and the pros and cons of an eIND approval.